EMA Reasons for Rejection of CCI
Mar27

EMA Reasons for Rejection of CCI

New data from European Medicines Agency (EMA) confirms the tough position EMA is taking in regard to commercially confidential information (CCI). According to the European Medicines Agency’s “EMA Update on Clinical Data Publication” published on 29 January, 2018, 76% of CCI instances were rejected in 2017. Interestingly, the EMA has provided further insight on how they are considering CCI by citing five reasons for rejection.

Read More
The Many Challenges of Narrative Writing
Mar13

The Many Challenges of Narrative Writing

Narratives are an essential part of any programs’ story, but often become cumbersome due to the many challenges of narrative writing.

Read More
Thinking Beyond eCTD Publishing
Mar06

Thinking Beyond eCTD Publishing

While finding the right publishing vendor provides tremendous value to an organization short on internal resources, it is important to be thinking beyond eCTD publishing. Pairing with a vendor that can offer extensive regulatory and communications strategy, science and solutions experience brings numerous synergies.

Read More
Tips For A Successful eCTD Conversion
Feb13

Tips For A Successful eCTD Conversion

With the May, 2018 FDA mandate quickly approaching, conversion of paper IND’s, NDA’s, and DMF’s to eCTD format must happen soon. Here are some tips for a successful eCTD conversion.

Read More
Is Your Company Prepared for the FDA eCTD Mandate?
Feb06

Is Your Company Prepared for the FDA eCTD Mandate?

Here we are in 2018, and to the surprise of some and the consternation of many, some paper applications are still alive and well. However, their days are numbered. The May FDA eCTD mandate is upon us. Is your company prepared to implement the FDA’s regulations for eCTD submissions of INDs, NDAs and DMFs?  

Read More